Eli Lilly — GLP-1 Demand Insatiable, Manufacturing Catching Up
Tirzepatide (Zepbound/Mounjaro) generated $5.9B in Q1 2026, up 47% YoY. Lilly has committed $23B to expand manufacturing — a bet on demand lasting decades, not quarters. New oral GLP-1 (orforglipron) in Phase 3 could open the billion-person unaddressed market. LLY is 5–7% above its 20-day average after a recent pullback from highs — Accumulate. The 15-year runway for obesity and diabetes drugs is the clearest long-duration demand curve in healthcare right now.
Scores in this piece come from the ZonedInOut model. How the score works →
Get the Sunday Brief
One email a week, before the open: what the board did, which calls worked, which didn't, and what changed. Free. No spam, unsubscribe anytime.